Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IDT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIDT Corp appoints William Conkling to Board as Audit Committee Chair following director resignation
Filed June 11, 2026 · Period ending June 9, 2026 · ~1 min read
Key Changes
-
medium
William Conkling appointed to Board on June 9, 2026, designated as independent director and named Audit Committee Chairman and Financial Expert, filling vacancy from Katsof's departure.
Item 5.02 verify on EDGAR → -
medium
Director Irwin Katsof resigned from Board and all committees on June 9, 2026. Filing explicitly states resignation was not due to any disagreement with Company operations, policies, or practices.
Item 5.02 verify on EDGAR → -
low
Conkling will also serve on Compensation and Corporate Governance Committees. He brings pharmaceutical industry experience as current CCO of Protara Therapeutics and former CEO of Rafael Holdings.
Item 5.02 verify on EDGAR →
Summary
IDT Corporation executed a same-day board transition on June 9, 2026, with director Irwin Katsof resigning and William Conkling immediately appointed to fill the vacancy. The swift replacement suggests planned succession rather than crisis management, reinforced by the filing's explicit statement that Katsof's departure involved no disagreements with company operations or policies.
Conkling's appointment carries weight for governance oversight. As the new Audit Committee Chairman and designated Financial Expert, he assumes critical responsibility for financial reporting oversight and internal controls.
His independence certification under NYSE standards and his placement on all three key committees (Audit, Compensation, and Corporate Governance) positions him as a central figure in board oversight functions. Retail investors should monitor the upcoming 2026 annual meeting, where Conkling's term expires and shareholders will vote on his continuation. His pharmaceutical background differs from IDT's telecom and fintech focus, so watch for any strategic shifts or new business development initiatives that might leverage his life sciences commercialization expertise.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 9, 2026, the Board appointed William Conkling to the Board. Mr. Conkling's term will expire at the Company’s annual meeting of stockholders in 2026. The Board has determined that Mr. Conkling is “independent” in accordance with the listing standards of the New York Stock Exchange, the Company’s internal policies, and the rules and regulations of the Securities and Exchange Commission (the “SEC”). Mr. Conkling is expected to serve as the Chairman of the Audit Committee and be the Audit Committee Financial Expert and also serve as a member of the Compensation Committee and the Corporate Governance Committee.
William Conkling was appointed to the Board on June 9, 2026, filling the vacancy left by Katsof. He is designated as independent and will chair the Audit Committee while serving as the Audit Committee Financial Expert. He will also serve on the Compensation and Corporate Governance Committees, indicating significant oversight responsibilities.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Mr. Conkling, age 55, has served as the Chief Commercial Officer of Protara Therapeutics Inc. since June 2025. He served as the Chief Executive Officer of Rafael Holdings, Inc. (NYSE: RFL) from February 2022 to May 2025 and served as the Chief Commercial and Business Officer of Rafael Holdings, Inc. from March 2021 to January 2022.
Conkling brings pharmaceutical and life sciences experience, currently serving as Chief Commercial Officer at Protara Therapeutics and previously as CEO of Rafael Holdings. His background includes commercialization roles at Immunomedics (acquired by Gilead for $21 billion) and over 10 years at Novartis, suggesting expertise in commercial strategy and business development.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 11, 2026 · How we verify